Scancell Holdings Share News (SCLP)

Scancell Holdings Information

Buy SCLP Shares
Add SCLP to Watchlist
Add SCLP to Alert

Share Price Information for Scancell Holdings (SCLP)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 10.00

Bid: 9.50

Ask: 10.50

Change: 0.00 (0.00%)

Spread: 1.00 (10.526%)

Open: 0.00

High: 0.00

Low: 0.00

Prev. Close: 9.875

Last checked at -

Scancell Holdings updates on clinical trial of melanoma vaccine

Tue, 29th Jan 2013 09:05

Scancell Holdings said Tuesday it edged closer to completing clinical trials of a vaccine for the treatment of melanoma. The developer of therapeutic cancer vaccines recruited and treated the final patient in the second phase of tests for SCIB1, a DNA ImmunoBody injection.The trial is being conducted in five UK centres in patients with Stage III/IV disease to assess the safety of the treatment and the immune response. Patients are being treated with a 4.0mg dose of SCIB1, five times over six months. Last month Scandell released findings from the first phase of the study which showed SCIB1 produced an immune response that may benefit patients with malignant melanoma. At the same the group also announced approval from regulators to treat an extra group of patients with a higher 8.0mg dose of the vaccine."As expected, the recruitment of patients in the second part of the trial proceeded faster than recruitment for the first part of the trial, as we were not constrained by the cohort study design requiring sequential dose escalation, and there were more patients available with earlier stage disease," said Lindy Durrant, Joint Chief Executive Officer (CEO) of Scancell Holdings and Professor of Cancer Immunotherapy at Nottingham University."The recruitment and dosing of the final patient in part two gives us confidence that this phase of the study will be completed by the end of 2013, consistent with previous expectations."Shares were down 0.59% to 42.25p at 9:19 Tuesday. RD

More News

20 Jul 2016 12:35

Scancell granted product licence extension from Ichor Medical Systems

(ShareCast News) - Scancell, the developer of immunotherapies for cancer treatments, was granted a product licence option extension from Ichor Medical Systems. The extension is to licence the commercial use of Ichor's TriGrid electroporation delivery system with SCIB1, Scancell's ImmunoBody vaccine,

20 Jul 2016 08:30

Scancell Licence To Use TriGrid Technology Extended To 2018 (ALLISS)

13 Jul 2016 09:19

Scancell Says Review Supporting Potential Of Moditope Published

6 Jul 2016 08:28

Scancell Holdings SCIB1 Cancer Drug Shows "Compelling" Survival Data

17 Jun 2016 12:24

Scancell suspends dosing with current supplies of SCIB1 for melanoma

(ShareCast News) - Shares in drug developer Scancell Holdings plunged almost 17% after it suspending dosing with current clinical trial supplies of SCIB1 for melanoma with immediate effect. Patients would be notified as soon as possible. AIM-quoted Scancell said quality-control analysis showed the

17 Jun 2016 09:46

WINNERS & LOSERS SUMMARY: National Grid Hit By Break-Up Recommendation

17 Jun 2016 08:10

UPDATE 1-Scancell slumps as drug problem disrupts melanoma trial

(Adds latest shares, details) LONDON, June 17 (Reuters) - British drug developer Scancell has suspended dosing in a cancer clinical trial because of quality problems with an immunotherapy treatment, wiping more than a quarter off the value of its shares on Friday. The company said te

17 Jun 2016 07:46

BUZZ-Scancell: drug problem spurs worst day in 3 yrs

** Drug developer Scancell's shares down 27 pct, worst day in nearly three years, after suspends dosing in a cancer clinical trial because of quality problems with its immunotherapy treatment SCIB1 ** Co says current supplies of drug no longer meet original specification and are no longer s

17 Jun 2016 06:51

Drug problem forces Scancell to suspend cancer trial dosing

LONDON, June 17 (Reuters) - British drug developer Scancell said on Friday it was suspending dosing in a cancer clinical trial because of quality problems with its immunotherapy treatment SCIB1. The company said tests showed the product, which is being assessed for melanoma, was "no longer

17 Jun 2016 06:44

Scancell Holdings Suspends Dosing In SCIB1 Cancer Treatment Trials

2 Jun 2016 07:57

Scancell's ImmunoBody Platform Chosen For Preclinical Glioma Study

19 May 2016 05:55

CORRECT (18/05): Scancell Shuffles Board As New US Offices Open

18 May 2016 08:31

BROKER RATINGS SUMMARY: Goldman Upgrades Booker, Panmure Cuts Meggitt

18 May 2016 08:06

Scancell Shuffles Board As New US Offices Open, Plans For Oxford Base

4 Apr 2016 11:47

Scancell raises £6.2m in placing and open offer

(ShareCast News) - Scancell revealed the final results of its placing and open offer on Monday, with a few more subscriptions received since the firm's last update on 1 April. The AIM-traded company had announced on Friday that it had received subscriptions for 16,048,593 new ordinary shares of the

Latest Share Chat

Scancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Scancell Holdings updates on clinical trial of melanoma vaccine

Login to your account

Quickpicks are a member only feature

Login to your account